MA34908B1 - Comprimé dispersible par voie orale - Google Patents

Comprimé dispersible par voie orale

Info

Publication number
MA34908B1
MA34908B1 MA36182A MA36182A MA34908B1 MA 34908 B1 MA34908 B1 MA 34908B1 MA 36182 A MA36182 A MA 36182A MA 36182 A MA36182 A MA 36182A MA 34908 B1 MA34908 B1 MA 34908B1
Authority
MA
Morocco
Prior art keywords
preparation
drug
granules
polyol
dispersible tablet
Prior art date
Application number
MA36182A
Other languages
English (en)
French (fr)
Inventor
Yutaka Tanoue
Tetsuya Matsuura
Yutaka Yamagata
Naoki Nagahara
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34908(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34908B1 publication Critical patent/MA34908B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
MA36182A 2011-01-17 2012-01-16 Comprimé dispersible par voie orale MA34908B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011007371 2011-01-17
JP2011227333 2011-10-14
PCT/JP2012/051279 WO2012099260A1 (en) 2011-01-17 2012-01-16 Orally dispersible tablet

Publications (1)

Publication Number Publication Date
MA34908B1 true MA34908B1 (fr) 2014-02-01

Family

ID=45567081

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36182A MA34908B1 (fr) 2011-01-17 2012-01-16 Comprimé dispersible par voie orale

Country Status (24)

Country Link
US (6) US20120282191A1 (cg-RX-API-DMAC7.html)
EP (1) EP2665465A1 (cg-RX-API-DMAC7.html)
JP (3) JP5600747B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140014134A (cg-RX-API-DMAC7.html)
CN (1) CN103429223A (cg-RX-API-DMAC7.html)
AR (1) AR084865A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012207818B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013017600A2 (cg-RX-API-DMAC7.html)
CA (1) CA2824430A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013002033A1 (cg-RX-API-DMAC7.html)
CO (1) CO6791611A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130380A (cg-RX-API-DMAC7.html)
EA (1) EA201391053A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012825A (cg-RX-API-DMAC7.html)
IL (1) IL227357A0 (cg-RX-API-DMAC7.html)
MA (1) MA34908B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013008314A (cg-RX-API-DMAC7.html)
PE (1) PE20140255A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501512A1 (cg-RX-API-DMAC7.html)
SG (1) SG191964A1 (cg-RX-API-DMAC7.html)
TW (1) TW201309347A (cg-RX-API-DMAC7.html)
UY (1) UY33869A (cg-RX-API-DMAC7.html)
WO (1) WO2012099260A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201305567B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
CN103989643B (zh) * 2013-07-26 2018-10-30 武汉先路医药科技有限公司 含有雷美替胺和共聚维酮的片剂
EP3027179B1 (en) * 2013-07-31 2018-10-17 Intelgenx Corporation Instantly wettable oral film dosage form without surfactant or polyalcohol
CA2888219C (en) * 2014-02-07 2018-07-10 Scilabs Pharmaceuticals, Inc. All natural, non-toxic sublingual drug delivery systems
CN105853379A (zh) * 2016-03-31 2016-08-17 北京万全德众医药生物技术有限公司 一种雷美替胺分散片及其制备工艺
CN106389361A (zh) * 2016-03-31 2017-02-15 北京万全德众医药生物技术有限公司 一种含有雷美替胺的口腔崩解片及其制备方法
CN117482062A (zh) 2016-05-06 2024-02-02 雀巢产品有限公司 缬草组合物和相关方法
CN106038502A (zh) * 2016-07-01 2016-10-26 北京万全德众医药生物技术有限公司 一种雷美替胺口崩片及其制备方法
CN110996938A (zh) * 2017-07-13 2020-04-10 美治医药科技有限公司 雷美替胺的药物组合物及其使用方法
BR112020021852A2 (pt) 2018-05-02 2021-02-23 Ferring B.V. formulações farmacêuticas aperfeiçoadas
JP7552146B2 (ja) * 2019-08-28 2024-09-18 小野薬品工業株式会社 イバブラジンを含有する錠剤
CN113243444A (zh) * 2020-02-13 2021-08-13 罗盖特公司 作为口香糖中的填充剂的多孔淀粉
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物
CN115778925A (zh) * 2022-12-26 2023-03-14 湖北广济医药科技有限公司 一种雷美替胺口溶膜剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US20010014340A1 (en) * 1996-06-14 2001-08-16 Motohiro Ohta Intrabuccally rapidly disintegrating tablet
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
TWI271198B (en) 1999-02-15 2007-01-21 Dainippon Sumitomo Pharma Co Tables disintegrating rapidly in the oral cavity
WO2001015735A1 (fr) * 1999-08-26 2001-03-08 Takeda Chemical Industries, Ltd. Matrice adherant a la muqueuse nasale
AU2001248751A1 (en) 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US7008642B1 (en) * 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
FR2834890B1 (fr) 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US20040161459A1 (en) * 2002-12-31 2004-08-19 Ngoc Do Fast-dissolve tablet technology
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
AU2006231752B2 (en) * 2005-04-04 2012-03-01 Takeda Pharmaceutical Company Limited Preventive or remedy for depression or anxiety neurosis
US20100011960A1 (en) * 2005-07-18 2010-01-21 Colin Lawrence Electrostatic Air Filter
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
JP5053865B2 (ja) * 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
KR20090029200A (ko) 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
US7797869B2 (en) * 2006-07-10 2010-09-21 Tollis David R Multi-section display and utility stanchion
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2680536A1 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
MX2009010878A (es) * 2007-04-11 2010-03-26 John A Mccarty Pastilla de melatonina y metodos de preparacion y uso.
US20090105490A1 (en) * 2007-07-12 2009-04-23 Nurit Perlman Polymorphic forms of ramelteon and processes for preparation thereof
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2009136240A (ja) 2007-12-10 2009-06-25 Lion Corp チューインガム組成物
CN102065845A (zh) 2008-06-11 2011-05-18 阿斯利康(瑞典)有限公司 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物
US7833819B2 (en) * 2008-07-23 2010-11-16 Aptina Imaging Corporation Method and apparatus for decreasing storage node parasitic charge in active pixel image sensors
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP2011007371A (ja) 2009-06-23 2011-01-13 Sanyo Electric Co Ltd 空気調和機
JP5513936B2 (ja) * 2010-03-10 2014-06-04 全星薬品工業株式会社 口腔内崩壊製剤
JP5523913B2 (ja) 2010-04-21 2014-06-18 スタンレー電気株式会社 光源装置および照明装置

Also Published As

Publication number Publication date
CO6791611A2 (es) 2013-11-14
JP2016053094A (ja) 2016-04-14
US20120282191A1 (en) 2012-11-08
KR20140014134A (ko) 2014-02-05
NZ613265A (en) 2015-08-28
IL227357A0 (en) 2013-09-30
JP2013544230A (ja) 2013-12-12
ECSP13012825A (es) 2013-10-31
US20130035385A1 (en) 2013-02-07
ZA201305567B (en) 2014-10-29
CA2824430A1 (en) 2012-07-26
US20140235709A1 (en) 2014-08-21
US20130035384A1 (en) 2013-02-07
EP2665465A1 (en) 2013-11-27
TW201309347A (zh) 2013-03-01
US20170065553A1 (en) 2017-03-09
US20140235879A1 (en) 2014-08-21
UY33869A (es) 2012-08-31
AU2012207818B2 (en) 2015-05-14
SG191964A1 (en) 2013-08-30
BR112013017600A2 (pt) 2016-10-18
CN103429223A (zh) 2013-12-04
JP2014198723A (ja) 2014-10-23
PH12013501512A1 (en) 2013-09-16
US8642649B2 (en) 2014-02-04
MX2013008314A (es) 2013-09-26
EA201391053A1 (ru) 2013-12-30
WO2012099260A1 (en) 2012-07-26
AR084865A1 (es) 2013-07-10
CL2013002033A1 (es) 2014-01-03
AU2012207818A1 (en) 2013-05-02
JP5600747B2 (ja) 2014-10-01
US8642648B2 (en) 2014-02-04
CR20130380A (es) 2013-10-09
PE20140255A1 (es) 2014-03-11

Similar Documents

Publication Publication Date Title
MA34908B1 (fr) Comprimé dispersible par voie orale
MA30807B1 (fr) Compositions pharmaceutiques.
MX337603B (es) Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
MX2010011381A (es) Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.
HK1199259A1 (en) Lysophosphatidic acid receptor antagonists
WO2010081443A3 (en) Dosage forms of tyrosine kinase inhibitors
EP2602314A4 (en) MUTANT MICROORGANISM WITH HIGH PRODUCTION OF CADAVERIN AND METHOD FOR PRODUCING CADAVERIN THEREWITH
PH12014500853A1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
WO2005107721A3 (en) Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
TW200621307A (en) Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion
TN2013000286A1 (en) Orally dispersible tablet
WO2011094434A3 (en) 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
Barresi et al. Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry
WO2008059298A3 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
WO2008056059A3 (fr) Derives de 4-azasteroles, leurs procedes de synthese et leur utilisation a titre de medicament
NO20045657L (no) Fremgangsmate ved fremstilling av fast doseringsform for desmopressin
MA30312B1 (fr) Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
PH12016502540A1 (en) Pharmaceutical dosage forms
CA2669324A1 (en) Method for preparing sustained release tablet
Lazzarato et al. Broad spectrum metallo beta-lactamases inhibitors: New tools against clinically-relevant carbapenemases
MA51982A (fr) Formulation de medicaments a liberation ranlentie avec une couche exterieure comprenant un polymere degradable par des enzymes, sa composition et son processus de production
Qureshi Expansion of the Anionic Amino-Cope Cascade and Deuteration of Monomers for the Creation of Perdeuterated Polymers
Mishra et al. Pantoprazole and its enteric coating polymer concentration for stable coating in acid media in stomach